Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells ; volume:12 ; number:1 ; day:22 ; month:9 ; year:2012 ; pages:1-11 ; date:12.2012
BMC cancer ; 12, Heft 1 (22.9.2012), 1-11, 12.2012
- Urheber
-
Papa, Anne-Laure
- Beteiligte Personen und Organisationen
-
Basu, Sudipta
Sengupta, Poulomi
Banerjee, Deboshri
Sengupta, Shiladitya
Harfouche, Rania
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-419
- URN
-
urn:nbn:de:1111-201603042857
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Papa, Anne-Laure
- Basu, Sudipta
- Sengupta, Poulomi
- Banerjee, Deboshri
- Sengupta, Shiladitya
- Harfouche, Rania
- SpringerLink (Online service)
Ähnliche Objekte (12)
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)